Lungpacer Medical is developing a novel therapeutic solution for preserving the integrity and strength of the diaphragm muscle The objective of the company is to develop and commercialize a novel therapeutic solution that addresses the significant health and cost issues associated with mechanical ventilation of critically ill patients in hospital Intensive Care Units (ICU). It is designed to activate the diaphragm using a temporary, minimally invasive, transvascular nerve stimulation approach that is expected to save many lives, improve surviving patient outcomes and greatly reduce hospital care costs. In addition, the paced diaphragm is expected to restore negative pressure ventilation, thereby potentially providing a more physiological respiratory pattern and reducing the levels of positive pressure ventilation and its harmful effects on the lungs. Lung Pacer was founded in 2009 and is headquartered in Vancouver, British Columbia, Canada.
Something looks off?